Status:
COMPLETED
Indocyangreen Elimination in Cirrhosis and Acute Liver Failure
Lead Sponsor:
Heidelberg University
Conditions:
Acute Liver Failure
Liver Cirrhosis
Eligibility:
All Genders
18-80 years
Brief Summary
Indocyangreen (ICG)is totally biliary eliminated and corresponds to hepatocyte function and liver perfusion. The ICG-clearance will be evaluated as a prognostic marker in liver disease.
Detailed Description
patients with acute liver failure or advanced liver disease will be studied. ICG-clearance will be correlated with established clinical scores and outcome.
Eligibility Criteria
Inclusion
- acute liver failure OR end-stage liver disease
- normal hepatic perfusion by doppler ultrasound
Exclusion
- portal vein thrombosis
- allergy to ICG or iodine
- thyroid disease
Key Trial Info
Start Date :
October 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00245310
Start Date
October 1 2005
End Date
October 1 2010
Last Update
October 11 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Heidelberg
Heidelberg, Germany, 69120